Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the clinical and molecular history of 5-alpha reductase deficiency, highlighting its role in male sexual differentiation and potential therapeutic applications, but reports no new research outcomes.

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.

This study found that the evodiamine derivative 2-16 exhibited the highest antitumor activity and a broad spectrum of activity against various human cancer cell lines, with improved solubility.

This chapter reviews selective androgen receptor modulators, discussing their therapeutic potential beyond current androgen applications, and reports no new clinical findings.

This study describes a case where finasteride treatment for benign prostatic hypertrophy was associated with gynecomastia in a 62-year-old man, which resolved after the drug was discontinued.

This review discusses current challenges in selective androgen receptor modulator discovery and preclinical evaluation and reports no new results, emphasizing the need for basic research to improve safety and selectivity.

This study suggests that the use of 5α-reductase inhibitors in men may be associated with macular abnormalities, characterized by cystoid changes and foveal cavitation, potentially progressing to more severe defects.

This study discusses how testosterone exerts its effects directly or through conversion to metabolites, DHT and estradiol 17β, each influencing different physiological processes, noting that DHT conversion is necessary for certain effects but not for muscle, bone, or erythropoiesis impacts.

This review discusses the evolution of Cereblon ligands in PROTAC technology, highlighting chemical innovations that may enhance drug-likeness and applicability in protein degradation, while noting challenges and future research directions.

This study used an in silico/in vitro approach to identify potential inhibitors of the enzyme SRD5A2, finding that the androgen receptor modulator MK-0773 is a moderate inhibitor, although it does not act as a covalent inhibitor like finasteride.

This commentary discusses the historical understanding of castration's effects on benign prostatic hyperplasia and reports no new clinical findings.

This study reports that incomplete information in a reverse supply chain can lead to efficiency losses, but a two-part tariff contract for the remanufacturer may improve performance by eliciting private information from collectors.

This chapter reviews the role of androgen receptors in mediating the actions of androgens in specific tissues and provides no new experimental findings.

This article reviews treatment options for male androgenetic alopecia, including their distinct aims of arresting progression, stimulating regrowth, and concealing hair loss, and reports no new clinical results.

This study supports the conclusion that the hormetic dose-response model is the most prevalent and fundamental model in biological and biomedical sciences, applicable to a wide range of clinical conditions.

This review discusses the roles and mechanisms of Wnt signaling in embryonic and adult stem cells and its association with cancers, and reports no new experimental findings.

This study found that newly synthesized steroidal trienones demonstrated stronger 5α-reductase inhibitory activity compared to dienones in various biological models, suggesting potential for developing enhanced antiandrogenic drugs.

This review discusses the role of the TMPRSS2 gene in SARS-CoV-2 infection susceptibility and outcomes, highlighting its differential expression in ethnic groups and potential as a target for COVID-19 treatments, but reports no new results.

This article reviews the potential of combining antiandrogenic and antiestrogenic treatments for BPH, highlighting aromatase inhibitors, but presents no new clinical results; further research is needed.

This review discusses hormonal manipulation for conditions like prostatic disorders and skin issues and highlights promising treatments like casodex and finasteride, but it reports no new clinical results.

This study found a high prevalence of beard and eyebrow alopecia in male patients with frontal fibrosing alopecia, and suggests a potential link between hormonal imbalances and the condition.

The researchers reported that cancer incidences are rising over time in developed countries, with potential carcinogenic drivers including advancing age, estrogen, decreasing vitamin D3, and Human Papillomavirus.

This review summarizes current and emerging treatments for common hair loss conditions, highlighting good evidence for androgenetic alopecia but noting the lack of long-term data for alopecia areata and cicatricial alopecias.

Accidental findings have led to new hair treatment discoveries, like using blood pressure and diabetes medications for hair loss and unwanted hair.

In this study, patients with larger prostates were observed to have a higher prevalence of androgenetic alopecia.

This study found that Monascus cursory extraction reduced baldness, prostate hyperplasia, and tumor incidence in animal models of androgen-related diseases, suggesting it may be a promising new therapeutic candidate.

This article concludes that finasteride is a safe treatment for androgenetic alopecia and does not increase the risk of high-grade prostate cancer, despite past concerns from the Prostate Cancer Prevention Trial.

This review covers recent advances in prostate cancer risk assessment, diagnosis, and treatment but does not report new clinical results; further studies on androgen deprivation therapy's cardiovascular risks are particularly noted.

This study found that finasteride-loaded liposomal formulations achieved significantly higher skin permeation and deposition compared to conventional gels and solutions, suggesting potential for effective topical application.

This study examined the most common chemotherapy side effects among patients with prostate, bladder, and testicular cancer, noting hair loss, fatigue, and decreased appetite as frequent symptoms.